GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (XBRU:ARGX) » Definitions » Machinery, Furniture, Equipment

argenx SE (XBRU:ARGX) Machinery, Furniture, Equipment : €0 Mil (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is argenx SE Machinery, Furniture, Equipment?

argenx SE's Machinery, Furniture, Equipment for the quarter that ended in Mar. 2025 was €0 Mil.

argenx SE's quarterly Machinery, Furniture, Equipment increased from Sep. 2024 (€0 Mil) to Dec. 2024 (€10 Mil) but then declined from Dec. 2024 (€10 Mil) to Mar. 2025 (€0 Mil).

argenx SE's annual Machinery, Furniture, Equipment increased from Dec. 2022 (€4 Mil) to Dec. 2023 (€5 Mil) and increased from Dec. 2023 (€5 Mil) to Dec. 2024 (€10 Mil).


argenx SE Machinery, Furniture, Equipment Historical Data

The historical data trend for argenx SE's Machinery, Furniture, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Machinery, Furniture, Equipment Chart

argenx SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Machinery, Furniture, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.87 2.72 3.76 5.09 10.23

argenx SE Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Machinery, Furniture, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 10.23 -

argenx SE Machinery, Furniture, Equipment Calculation

Machinery, Furniture, Equipment represents those fixed assets specifically dealing with tools, equipment and office furniture.


argenx SE Business Description

Industry
Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.